Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
---|---|---|---|---|---|---|
2011 | Spread of methicillin-resistant Staphylococcus aureus between the community and the hospitals in Asian countries: An ANSORP study | Song J.-H.; PO-REN HSUEH ; Chung D.R.; Ko K.S.; Kang C.-I.; Peck K.R.; Yeom J.-S.; Kim S.-W.; Chang H.-H.; Kim Y.-S.; Jung S.-I.; Son J.S.; Man-Kit So T.; Lalitha M.K.; Yang Y.; Huang S.-G.; Wang H.; Lu Q.; Carlos C.C.; Perera J.A.; Chiu C.-H.; Liu J.-W.; Chongthaleong A.; Thamlikitkul V.; Hung Van P. | Journal of Antimicrobial Chemotherapy | 307 | 286 | |
2020 | TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer | Oxnard G.R.; CHIH-HSIN YANG ; Yu H.; Kim S.-W.; Saka H.; Horn L.; Goto K.; Ohe Y.; Mann H.; Thress K.S.; Frigault M.M.; Vishwanathan K.; Ghiorghiu D.; Ramalingam S.S.; Ahn M.-J. | Annals of Oncology | 272 | 228 | |
2020 | Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial | Wu Y.-L.; Cheng Y.; Zhou J.; Lu S.; Zhang Y.; Zhao J.; Kim D.-W.; Soo R.A.; Kim S.-W.; Pan H.; Chen Y.-M.; Chian C.-F.; Liu X.; Tan D.S.W.; Bruns R.; Straub J.; Johne A.; Scheele J.; Park K.; CHIH-HSIN YANG ; Liu Z.; Chen X.; Wang M.; Yu S.; Zhang H.; Fang J.; Li W.; Yang C.-H.; Chang G.-C.; Hsia T.-C.; Yang C.-T.; Wang C.-C.; Cho B.C.; Lee K.H.; Kim Y.-C.; An H.J.; Woo I.S.; Cho J.Y.; Shin S.W.; Lee J.-S.; Kim J.-H.; Yoo S.S.; Kato T.; Shinagawa N.; Tan S.W.D.; Ngo L.S.-M.; Ratnavelu K.; Ahmad A.R.; Liam C.K.; de Marinis F.; Tassone P.; Molla A.I.; Calles Blanco A.; Lazaro Quintela M.E.; Felip Font E.; Dingemans A.-M.; Bui L. | The Lancet Respiratory Medicine | 161 | 128 | |
2021 | Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients with EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial | Zhou C.; Ramalingam S.S.; Kim T.M.; Kim S.-W.; CHIH-HSIN YANG ; Riely G.J.; Mekhail T.; Nguyen D.; Garcia Campelo M.R.; Felip E.; Vincent S.; Jin S.; Griffin C.; Bunn V.; Lin J.; Lin H.M.; Mehta M.; J?nne P.A. | JAMA Oncology | 163 | 127 |